Biocon

Timeline

1. 1978Kiran Mazumdar-Shaw starts Biocon India Private Limited in Bengaluru as the Indian partner of the Irish enzyme maker Biocon Biochemicals.starting capital of about 10,000 dollars
2. 1979Becomes the first Indian company to manufacture and export enzymes to the United States and Europe.
3. 1980sThe enzyme business is joined by a growing share of pharmaceuticals made for the Indian domestic market.
4. 1989Unilever buys Biocon Biochemicals in Ireland and merges it into its subsidiary Quest International.
5. 1993Syngene International is established as the group's contract research arm.
6. 1998Unilever sells its holding to Biocon's Indian owners, reuniting the two sides of the original partnership under Indian control.
7. 2000Biocon Biologics is founded to hold the biosimilar business.
8. 2001The American regulator approves lovastatin, Biocon's first approval in a regulated market.
9. 2003Biocon Biopharmaceuticals is set up as a joint venture with the Cuban institute CIMAB to develop monoclonal antibodies and cancer vaccines.
10. 2004Biocon lists on the Indian exchanges in the country's first biotechnology initial public offering.oversubscribed about 33 times, first day value about 1.11 billion dollars
11. 2005Biocon Park opens on about 35 hectares outside Bengaluru as the group's research and manufacturing campus.
12. 2008Acquires a 70 per cent stake in the German pharmaceutical marketing company AxiCorp GmbH and starts NeoBiocon in Abu Dhabi.
13. 2009Announces a strategic collaboration with Mylan to enter the global generic biologics market.
14. 2013Launches ALZUMAb, its own monoclonal antibody for psoriasis.
15. 2014Launches CANMAb, a biosimilar trastuzumab for breast cancer.
16. 2015Syngene International is listed separately on the Bombay and National Stock Exchanges.
17. 2016Becomes the first Indian company to launch a biosimilar insulin glargine pen in Japan, and sets up a biologics facility in Bengaluru with Amgen.
18. 2017The American regulator approves the Mylan and Biocon biosimilar of the cancer drug Herceptin.
19. 2018European regulators clear the biosimilar insulin glargine, and Sandoz signs a global biosimilar partnership with Biocon.
20. 2021Semglee becomes the first interchangeable biosimilar approved in the United States for diabetes, and Serum Institute Life Sciences takes 15 per cent of Biocon Biologics.
21. 2022Biocon Biologics buys the biosimilar assets of Viatris for 3.34 billion dollars, and Biocon sells shares in Syngene.
22. 2025Announces the full integration of Biocon Biologics at a valuation of 5.5 billion dollars, and discontinues production of the low cost insulin glargine biosimilar Semglee in December.
23. 2026The integration completes on 31 March, a 4,150 crore rupee share sale funds the Viatris buyout, and Shreehas Tambe becomes chief executive of the combined company.

What it does

Biocon Limited is an Indian biopharmaceutical company headquartered in Electronic City, Bengaluru, with its United States headquarters in Bridgewater, New Jersey. Its business has four parts: generic active pharmaceutical ingredients, which are the chemical compounds other companies work into finished medicines; biologics and biosimilars, which are medicines grown from living cells; branded formulations sold in India; and research services sold to other drug companies. Its active ingredients reach about 120 countries, including the United States and Europe.^[1]

The pharmacy counter is the easiest place to see the company. Its Indian brands include INSUGEN for recombinant human insulin, BASALOG for insulin glargine, BIOMAb EGFR for nimotuzumab, BLISTO for glimepiride with metformin, CANMAb for trastuzumab, Evertor for everolimus, TACROGRAF for tacrolimus, ALZUMAb for itolizumab and KRABEVA for bevacizumab. Between them these cover metabolics, oncology, immunotherapy and nephrology, which is a deliberate spread across therapeutic areas rather than a bet on one molecule.^[1]

Two subsidiaries carry the growth. Biocon Biologics, founded in 2000, holds the biosimilar portfolio and is the largest component of the group. Syngene International, established in 1993 and listed separately on the Indian exchanges, is a contract research and development organisation whose clients include several of the largest pharmaceutical companies in the world. The group also makes small molecule drugs and peptides, and it describes itself as an integrated biopharmaceutical company rather than as a generics maker, because the same fermentation and cell culture capacity serves both halves of the business.^[1][10]

History

Biocon was formed in 1978 as Biocon India Private Limited, a partner in India to the Irish brewing enzyme company Biocon Biochemicals Ltd. Kiran Mazumdar-Shaw, a brewing technologist who had trained as a master brewer in Australia, started it with about 10,000 dollars of capital after finding that Indian banks were not willing to back a young woman running a manufacturing business. The first products were enzymes for brewers, including the papaya enzyme papain and isinglass, a fish collagen extract used to clarify beer and wine.^[1][2]

The firsts came early. In 1979 Biocon became the first Indian company to manufacture and export enzymes to the United States and Europe, a market Indian suppliers were not expected to reach at the time because the customer relationship depended on consistent quality rather than on price alone. Through the 1980s the enzyme business was joined by a growing share of pharmaceuticals made for the Indian market, as the company moved from a single product relationship into a portfolio business with its own brand names.^[1][2]

In 1989 Unilever bought Biocon Biochemicals in Ireland and folded it into its subsidiary Quest International, which left the Indian company with a multinational partner it had not chosen. Unilever sold its holding to Biocon's Indian owners in 1998, reuniting the two sides of the original partnership under Indian control and leaving the company free to set its own direction without a global parent.^[1]

The listing followed in 2004. Biocon's initial public offering was the first by an Indian biotechnology company, was oversubscribed about 33 times, and closed its first day of trading with a market value of about 1.11 billion dollars, which made it the second Indian company to cross the billion dollar mark on its first day. The money raised, and the public shareholders behind it, changed how the company could fund research that would not produce a product for years.^[1][2]

From enzymes to medicines

The shift from enzymes to medicines was a business decision with a technical argument behind it. Fermentation, which Biocon already used to make enzymes, is also the basis for making statins and other small molecule drugs, so the company moved into those products as its brewing customers consolidated. By the late 1990s it was supplying statins and other active ingredients to Indian drug makers and beginning to look for overseas buyers with longer contracts.^[1][2]

Long term supply contracts gave it a dependable market rather than a single windfall, and at one point statins accounted for more than half of the company's revenue. Revenue rose from about 70 crore rupees in 1998 to about 500 crore rupees in 2004, the year the company went public. The regulated markets were the next target, and the first American approval, for lovastatin in 2001, opened a business in which a supplier has to be inspected and audited rather than merely cheap.^[1]

Research became the company's distinguishing habit rather than a slogan. Biocon directed about ten per cent of its revenue into research and development as of 2014, a much higher proportion than most Indian drug makers, and it has filed at least 950 patent applications. That spending is what allowed an enzyme company in Bengaluru to develop its own antibodies rather than only copying other companies' molecules, and it is the reason the Indian press has treated Biocon as a technology company rather than as a manufacturer.^[1]

Biosimilars and Biocon Biologics

A biosimilar is a licensed version of a biological medicine whose original patent has expired. It is far harder to copy than a chemical pill, because the product is grown in living cells and the manufacturing process, not the molecule alone, determines what comes out of the reactor. Biocon's biosimilar business sits inside Biocon Biologics, founded in 2000, which grew to become the group's largest component and the reason the company is known outside India.^[1]

The partnerships did the market making. In 2009 Biocon announced a strategic collaboration with Mylan to enter the global generic biologics market, under which Mylan held exclusive commercialisation rights in the United States, Canada, Japan, Australia, New Zealand and Europe through a profit sharing arrangement. In 2016 Biocon became the first Indian company to launch a biosimilar insulin glargine pen in Japan, and in 2017 the American regulator approved the Mylan and Biocon biosimilar of the cancer drug Herceptin.^[1][4][5]

The approvals then came in a run. European regulators cleared the biosimilar insulin glargine in 2018, and in 2021 the American regulator approved Semglee, an insulin glargine injection, as the first interchangeable biosimilar for diabetes in the United States. Interchangeable status matters commercially because a pharmacist can substitute the product without a new prescription, which is the closest thing the market has to a real price mechanism for a biological medicine. Sandoz, a division of Novartis, signed a global partnership with Biocon in 2018 to develop, make and sell several biosimilars in immunology and oncology.^[1][6]

Scale arrived through acquisition and then through a corporate simplification. In 2022 Biocon Biologics bought the biosimilar assets of Viatris for 3.34 billion dollars, which gave it the products and the commercial infrastructure in the developed markets in a single transaction. On 6 December 2025 Biocon announced it would buy in the minority of Biocon Biologics and make it wholly owned, at a valuation of 5.5 billion dollars, abandoning a planned public offering of the biosimilar business. The minority stakes held by Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine were taken out in a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares at 405.78 rupees each, and the residual Viatris stake was bought for 815 million dollars, of which 400 million dollars was cash. A share sale to institutional investors raised about 4,150 crore rupees and completed on 14 January 2026 to fund that cash payment.^[1][6]

Insulin and diabetes

Diabetes is the market where Biocon's biosimilar work has had the most visible effect on patients. Insulin glargine is a long acting basal insulin, and for years it was supplied in India and in emerging markets at prices set by the originator. Biocon's version was launched in India under the BASALOG brand and, through partners, in Japan, Europe and the United States, which turned a single molecule into a product sold in several regulatory regimes at once.^[1][4]

The American approval of Semglee in 2021 was the high point of that effort. The company had built the product with Viatris, then its biosimilar partner, and the approval was described at the time as historic for the category because no interchangeable biosimilar for diabetes had been cleared before. For a country where insulin is a routine and lifelong purchase, the promise was that substitution at the pharmacy counter would do what negotiation had not.^[1][6]

The end of that product was less comfortable. In December 2025 Biocon discontinued production of the low cost insulin glargine biosimilar Semglee, and the withdrawal contributed to a shortage of basal insulins in the United States as demand moved to other options, particularly Sanofi's Lantus. A company stopping work on a medicine it had introduced as a price breaker is a reminder that a biosimilar is a commercial proposition as well as a clinical one, and that the savings for patients last only while the challenger stays in the market.^[1]

Oncology and immunology

Biocon's move up the value chain is clearest in oncology, where it developed its own antibodies rather than only copying other companies' approved products. CANMAb, its biosimilar trastuzumab for breast cancer, was launched in India in 2014, and the company's own antibody programme produced ALZUMAb, or itolizumab, for psoriasis, which was launched in 2013 as the first indigenously developed monoclonal antibody of its kind in India.^[1][3]

The Indian market gave the company a testing ground where it could learn the biology and the pricing at the same time. The Mylan and Biocon biosimilar of the cancer drug Herceptin was approved in the United States in 2017 and in other regulated markets afterwards, which turned the pair's oncology portfolio from a domestic story into an export one and put an Indian made antibody into the American supply chain.^[5]

Immunology followed oncology because the antibody manufacturing platform is the same. An antibody based biologic for a skin disorder was launched in 2015, the hepatitis C combination of ledipasvir and sofosbuvir was launched in India under the CIMIVIR-L brand in 2015, and the immunoconjugate work done with IATRICa and the manufacturing agreement with Optimer for the antibiotic fidaxomicin all sat on capabilities built for the antibody products. That is the strategy in one line: build a platform once, then use it across several therapeutic areas instead of funding a separate plant for each.^[1][7][8]

Syngene and research services

Syngene International was established in 1993 as Biocon's contract research arm, and it is the part of the group that sells the company's skills rather than its own molecules. It works on research, development and manufacturing services for other drug companies, and it has worked with several of the ten largest pharmaceutical companies in the world, with clients including Amgen, Zoetis, GlaxoSmithKline and Bristol Myers Squibb. For a client, the arrangement buys capacity and a lower cost base; for Biocon, it produces revenue that does not depend on any product of its own passing a trial.^[1][10]

The business has four divisions: drug discovery services, dedicated research centres, development and devices, and manufacturing. Its drug discovery platform, SynVent, works on both small and large molecules, and its biologics arm signs the kind of long term supply agreements a client is unlikely to move once the site has been inspected and approved. In July 2022 Syngene signed a ten year agreement with Zoetis to manufacture the drug substance for Librela, a monoclonal antibody used to treat osteoarthritis in dogs, which is an unusual example of an Indian manufacturer becoming the long term supplier of a veterinary biologic.^[1][9]

Syngene was listed separately on the Bombay and National Stock Exchanges in 2015, which gave the contract research business its own currency for hiring scientists and its own shareholders to report to. Biocon has since trimmed its holding, selling shares in September 2022 and again in a bulk deal that took more than 1,220 crore rupees worth of the stock off its books. The parent still controls the subsidiary, and the divestment is best read as portfolio management rather than as a change of strategy.^[1][11]

Generic active ingredients and regulated markets

The oldest part of Biocon is still the largest by volume. Active pharmaceutical ingredients are the bulk chemicals that go into finished tablets and capsules, sold to other manufacturers rather than to patients, and the company makes statins, immunosuppressants and other small molecule products for that trade in roughly 120 countries. The business is unglamorous, but it is the reason the group had cash to spend on research before the biosimilars arrived.^[1]

The regulated markets are the ones that matter for margin. A supplier approved by the American and European regulators can sell at a different price from one that holds only an Indian licence, and Biocon began collecting those approvals in 2001 with lovastatin. The company's own estimates put the savings its generic production delivered to European healthcare systems at about 30 billion euros by 2022, a figure it uses to argue that generic and biosimilar competition is a public good rather than merely a business.^[1]

The small molecule and biologic businesses are now run as one portfolio, which is the practical meaning of the 2026 integration, and peptides sit between the two in manufacturing difficulty. For a company that began with brewing enzymes, the through line is fermentation and cell culture capacity applied to more valuable molecules as the chemistry allows, and the same assets that once made isinglass for beer now make antibodies for cancer treatment.^[1]

Manufacturing and facilities

Biocon's manufacturing is concentrated in Bengaluru, where the company runs two sites, with other facilities mainly in Asia. The physical centre of the group is Biocon Park, a campus built in 2005 on about 35 hectares outside the city, which houses research and manufacturing and has been described as carrying around 5,000 employees at its scale. The address is not incidental: a biotechnology plant needs large volumes of clean water and reliable power, and the campus was built where both were available.^[1][2]

Biologics manufacturing is the expensive kind. It needs clean rooms, cell culture capacity, water systems and cold chain, and every regulator whose market the products enter inspects the site, which is why companies in this business talk about facilities rather than about products when they explain their plans. The plant in Malaysia in 2010 and the Bengaluru biologics capacity built with Amgen in 2016 were both steps of that kind. Neither is an asset that can be added in a quarter, and that constraint is the barrier that keeps new entrants out.^[1]

Syngene adds a second set of sites, including a research and development centre in Hyderabad, an active ingredient plant at Mangalore and an expanded research facility in Bengaluru. The group's footprint therefore spreads across small molecule plants, biologic plants and research sites, which is what an integrated company means in practice: different regulatory regimes, different capital cycles and different customers sitting inside one balance sheet.^[1][9]

Revenue and financials

For the year ended 31 March 2025 Biocon reported revenue of about 16,470 crore rupees, operating income of about 4,374 crore rupees, a net profit of about 1,013 crore rupees, total assets of about 58,797 crore rupees and total equity of about 27,712 crore rupees. Analysts watch the operating line more closely than the net line, because the gap between the two in any given year tends to come from financing and one off items rather than from the trading business.^[1]

The shape of the group explains the numbers. Biosimilars now supply the growth; they are sold in the most demanding markets and they carry the heaviest fixed costs, which is why the profits of the biosimilar business move with the timing of approvals and product launches rather than with the volume of pills sold. Generics and active ingredients supply steadier revenue at thinner margins, and research services supply a revenue line that grows with other companies' research budgets rather than with Biocon's own pipeline.^[1]

The integration of Biocon Biologics changes how these numbers should be read. Once the subsidiary is wholly owned, the holding company discount that had weighed on the valuation disappears and the group reports as a single operating company focused on diabetes, oncology and immunology. The share sale completed in January 2026 brought in about 4,150 crore rupees, and the 815 million dollars paid to Viatris for the residual stake is the largest single cash outflow the company has committed to in this restructuring.^[1][6]

Shareholding and ownership

Biocon is a promoter controlled company. Kiran Mazumdar-Shaw, who founded it in 1978, is its executive chairperson and its largest shareholder, and the promoter group's holding has been reported at a little over a third of the equity in recent years. The rest trades on the National Stock Exchange and the Bombay Stock Exchange, where the shares carry the symbol BIOCON and the code 532523 respectively, and the company has been listed since 2004.^[1]

That ownership structure means the group's big decisions are made by the founder and merely reported to shareholders. The practical consequence is that Biocon can commit to research that will not produce revenue for a decade without the quarterly pressure a widely held firm would face, which is exactly what the antibody programme required. The cost is that succession depends on the founder's judgment, and the changes of chief executive at Biocon Biologics showed how much of that judgment stays with the chairperson.^[1][12]

The subsidiary structure has been the other lever on the balance sheet. Syngene was listed separately in 2015 and Biocon has since sold part of its holding in it, and Biocon Biologics was for a time part owned by Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine before the 2026 buy in. Both moves were ways of raising capital against one division without selling control of the group.^[1][11]

Employees and offices

The company reported about 16,545 employees as of March 2023, spread across two Bengaluru sites, the Biocon Park campus and facilities elsewhere in Asia. Headcount in a company like this is a measure of manufacturing capacity as much as of office work, because biological production and quality control are labour intensive in ways that chemical production is not, and a new biologic plant adds scientists before it adds revenue.^[1]

The jobs are unusually research heavy for an Indian drug maker. Biocon has argued over the years that its research spending and its Bengaluru base have kept a generation of scientists and engineers in India who would otherwise have moved abroad, and Biocon Park with its laboratories is the physical expression of that claim. The company has also treated the location as a business variable, on the reasoning that a plant's address decides the cost of water, power and staff.^[1][2]

Its registered headquarters is in Electronic City, Bengaluru, and the company operates a second centre of gravity in the United States, at Bridgewater in New Jersey, where the commercial side of the biosimilar business sits. The American presence is not a convenience: the largest biosimilar market in the world is there, and the sales, regulatory and legal functions have to be close to the customers and the regulator.^[1]

Acquisitions and partnerships

• Biocon Biochemicals and Unilever: the 1989 acquisition of the Irish partner by Unilever and the 1998 buyback by the Indian owners ended the original partnership and returned the company to Indian control.^[1]
• Biocon Biopharmaceuticals, a joint venture set up in 2003 with the Cuban institute CIMAB to develop and market monoclonal antibodies and cancer vaccines.^[1]
• AxiCorp GmbH, a 70 per cent stake bought in 2008, which gave Biocon a German marketing arm for its own products.^[1]
• Mylan, the 2009 collaboration that took Biocon's biosimilars into the developed markets under a profit sharing arrangement.^[1]
• Amgen, with which Biocon established a biologics facility in Bengaluru in 2016.^[1]
• Sandoz, the 2018 global partnership to develop, manufacture and commercialise biosimilars in immunology and oncology.^[1]
• Serum Institute Life Sciences, which took 15 per cent of Biocon Biologics in 2021 at a valuation of 4.9 billion dollars, with Biocon gaining access to 100 million doses of vaccines a year for 15 years.^[1]
• Viatris, whose biosimilar assets Biocon Biologics bought in 2022 for 3.34 billion dollars, and whose residual stake was bought out for 815 million dollars in 2026.^[1][6]

Founders and leadership

A company founded and still chaired by its founder is unusual in the Indian pharmaceutical industry, and Biocon's governance has moved in steps rather than in one break. Kiran Mazumdar-Shaw remains executive chairperson, and the company has repeatedly hired professional managers beneath her while leaving the strategic direction with the founder. Siddharth Mittal led the company as chief executive and managing director from December 2019 until he resigned effective 31 March 2026, having replaced Arun Chandavarkar.^[1]

The integration of Biocon Biologics brought a new structure. Effective 1 April 2026, Shreehas Tambe was appointed chief executive and managing director of Biocon Limited, the first chief executive of the combined company, and Kedar Upadhye was appointed chief financial officer. Mittal moved to another leadership role inside the group rather than leaving it, which kept the transition quiet at a time when the restructuring was the larger story.^[1]

The biosimilar subsidiary had its own succession trouble earlier. Christiane Hamacher, appointed chief executive of Biocon Biologics in March 2019, resigned in 2021 following differences with the chairperson. The company confirmed the departure and the press covered it without much detail. For a group that had promoted its subsidiary leaders as institutional figures, the exit was a reminder that in this company the final authority is the founder.^[1][12]

Competition

In biosimilars Biocon competes with the large generic companies that have built their own biologic platforms and with the originators whose products it copies. The insulin market puts it against Sanofi, Novo Nordisk and Eli Lilly, and the cancer antibody market puts it against Roche and the generics houses that have followed it into those molecules. Its advantage is cost of manufacture and early entry into each product; its disadvantage is that the originator can cut prices the moment a biosimilar arrives.^[1]

In active ingredients the competition is a long tail of Indian and Chinese manufacturers with lower costs and fewer inspections, which is why Biocon pushed toward the regulated markets where the barriers to entry are higher. In contract research, Syngene competes with the large global contract research organisations and with the captive research arms of the drug majors, and its pitch is cost, compliance and long term relationships rather than novelty.^[1][10]

In the Indian domestic market Biocon competes with the large Indian pharmaceutical companies, several of which earn far more than it does from branded formulations. Its answer has been to treat India as the launch market for products it intends to sell abroad, rather than as the main profit centre, which is the opposite of how most Indian drug makers use their home market.^[1]

Controversies and criticism

Biocon has had fewer public disputes than most companies of its size, and the criticism that has been recorded is mostly about price and access rather than about conduct. The most common charge, made on behalf of patients and by commentators, is that the company's biosimilars remain expensive in India even when they are cheaper than the imported originals, and the company's answer is that manufacture, trials and regulation cost what they cost.^[1]

The repeated change of chief executive at Biocon Biologics was reported as a governance concern, since the resignation followed differences with the chairperson rather than a business disagreement that had been disclosed. Governance analysts in the Indian press have at times noted the concentration of decision making in a founder chaired board, which is a structural feature of founder led firms rather than a finding against this particular company.^[1][12]

The most recent criticism concerns the withdrawal of the low cost insulin glargine biosimilar from the United States market in December 2025, which contributed to a shortage of basal insulins as patients were moved to other products, chiefly Sanofi's Lantus. Whatever the commercial logic of the decision, the episode shows a general problem with biosimilar competition: the savings for patients arrive only while the challenger chooses to stay in the market.^[1]

Reading the numbers

Biocon is best read as three clocks running at different speeds. The active ingredients business is a volume business that earns from plant utilisation and regulatory access, and it rewards patience rather than spending. The biosimilars business is a portfolio business that earns from approvals and market access, where a single successful filing can be worth more than several years of manufacturing efficiency. Syngene is a services business that earns from other companies' research budgets and is largely insulated from Biocon's own pipeline.^[1]

The number to watch is therefore not revenue but the mix inside it. When biologics grow faster than generics, the group's margin should improve and its capital spending should rise; when the reverse happens, revenue can hold while the quality of the earnings falls. The 2026 integration removes a layer of complexity from that picture by turning a holding company and a subsidiary into one set of accounts, which is the reason management gave for doing it in the first place.^[1][6]

For a reader trying to judge the company rather than the share price, the useful test is whether the biosimilar pipeline keeps producing products that reach the developed markets ahead of the competition. That is what has driven the growth since 2015, and it is the one thing the balance sheet cannot show.^[1]

Related entries